What the studies show
Small studies, often without blinding or a comparison group, published outside the indexed international literature. No independent replication.
Animal studies, cell studies, or anecdotes only. This is where almost every viral peptide sits. Promising and proven are different words for a reason.
- 1Searches of PubMed and trial registries for Semax human trials outside Russia.LYO literature search, September 2026No randomised trials meeting international reporting standards were identified.
In context
Semax is a seven-amino-acid peptide derived from ACTH, developed in Russia in the 1980s and registered there for stroke and cognitive indications. It is not approved in the EU, US or UK. The human literature is almost entirely Russian-language, largely uncontrolled or poorly reported by international standards, and has not been replicated by independent groups — which is why the cognitive and stroke claims sit at grade D despite the registration.
Semax is not approved (outside russia). Legal status differs by country — see the regulation section or the jurisdiction pages.
Questions
Is Semax proven to help with cognitive performance?
What studies are behind the grade?
Is Semax approved for this?
Other outcomes for Semax
- DStroke recoveryRussian trials, not independently replicated
- DAnxiety / stressNone controlled internationally
- DSafety in humansadverseNo systematic international data
Reviewed 2 September 2026. Grades count human evidence only; see how LYO grades. Not medical advice. Correct this page →